Alzheimer’s drugs might get into the brain faster with new ultrasound tool, study shows

Alzheimer’s drugs might get into the brain faster with new ultrasound tool, study shows

WASHINGTON — Scientists have found a way to help Alzheimer’s drugs seep inside the brain faster — by temporarily breaching its protective shield. The novel experiment was a first attempt in just three patients. But in spots in the brain where the new technology took aim, it enhanced removal of Alzheimer’s trademark brain-clogging plaque, researchers … Read more

Eight in 10 feel dementia is still misunderstood, research finds

Eight in 10 feel dementia is still misunderstood, research finds

Eight in 10 adults believe dementia is still misunderstood, according to research. Despite it being increasingly common, misconceptions remain because of a lack of knowledge or embarrassment, the poll of 2,000 Brits found. Seven in 10 (69 percent) believe it is a subject which is not talked about enough in society, with 73 percent putting … Read more

Dementia symptoms include seven behavioural changes – what to look for

Dementia symptoms include seven behavioural changes – what to look for

Dementia is a syndrome, which is a group of symptoms, related to the progressive decline of the brain. Most common in people over the age of 65, though it can affect anyone of any age. Due to the nature of dementia, the symptom we most commonly think of is memory loss. And as the condition … Read more

Dementia warning sign that you can spot in your hands as range of symptoms laid bare

Dementia warning sign that you can spot in your hands as range of symptoms laid bare

An early warning sign of dementia can be spotted by looking at your hands – as they may begin to tremble. While it’s expected that mental and physical function will decline as we get older, it can be hard to watch our loved ones deteriorate. Spotting the early signs of dementia can help prepare for … Read more

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Bristol Myers Squibb acquires Karuna Therapeutics for  billion, boosting neuroscience portfolio

NEW YORK — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna’s stock on … Read more